These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 39227453)

  • 1. An inherited genetic variant of the CEP72 gene is associated with the development of vincristine-induced peripheral neuropathy in female patients with aggressive B-cell lymphoma.
    Christofyllakis K; Kaddu-Mulindwa D; Lesan V; Rixecker T; Kos IA; Held G; Regitz E; Pfreundschuh M; Bittenbring JT; Thurner L; Poeschel V; Ziepert M; Altmann B; Bewarder M
    Ann Hematol; 2024 Nov; 103(11):4599-4606. PubMed ID: 39227453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic polymorphisms and vincristine-induced peripheral neuropathy in patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone therapy.
    Sawaki A; Miyazaki K; Yamaguchi M; Takeuchi T; Kobayashi K; Imai H; Tawara I; Ono R; Nosaka T; Katayama N
    Int J Hematol; 2020 May; 111(5):686-691. PubMed ID: 31993939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia.
    Diouf B; Crews KR; Lew G; Pei D; Cheng C; Bao J; Zheng JJ; Yang W; Fan Y; Wheeler HE; Wing C; Delaney SM; Komatsu M; Paugh SW; McCorkle JR; Lu X; Winick NJ; Carroll WL; Loh ML; Hunger SP; Devidas M; Pui CH; Dolan ME; Relling MV; Evans WE
    JAMA; 2015 Feb; 313(8):815-23. PubMed ID: 25710658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Inherited Genetic Variant in CEP72 Promoter Predisposes to Vincristine-Induced Peripheral Neuropathy in Adults With Acute Lymphoblastic Leukemia.
    Stock W; Diouf B; Crews KR; Pei D; Cheng C; Laumann K; Mandrekar SJ; Luger S; Advani A; Stone RM; Larson RA; Evans WE
    Clin Pharmacol Ther; 2017 Mar; 101(3):391-395. PubMed ID: 27618250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Precision Medicine in Childhood Cancer: The Influence of Genetic Polymorphisms on Vincristine-Induced Peripheral Neuropathy.
    Marangoni-Iglecias L; Rojo-Tolosa S; Márquez-Pete N; Cura Y; Moreno-Toro N; Membrive-Jiménez C; Sánchez-Martin A; Pérez-Ramírez C; Jiménez-Morales A
    Int J Mol Sci; 2024 Aug; 25(16):. PubMed ID: 39201483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenomics of Vincristine-Induced Peripheral Neuropathy Implicates Pharmacokinetic and Inherited Neuropathy Genes.
    Wright GEB; Amstutz U; Drögemöller BI; Shih J; Rassekh SR; Hayden MR; Carleton BC; Ross CJD;
    Clin Pharmacol Ther; 2019 Feb; 105(2):402-410. PubMed ID: 29999516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contribution of common and rare genetic variants in CEP72 on vincristine-induced peripheral neuropathy in brain tumour patients.
    Klumpers MJ; Brand ACAM; Hakobjan M; Gattuso G; Schiavello E; Terenziani M; Massimino M; Gidding CEM; Guchelaar HJ; Te Loo DMWM; Coenen MJH
    Br J Clin Pharmacol; 2022 Jul; 88(7):3463-3473. PubMed ID: 35150001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of association of the CEP72 rs924607 TT genotype with vincristine-related peripheral neuropathy during the early phase of pediatric acute lymphoblastic leukemia treatment in a Spanish population.
    Gutierrez-Camino A; Martin-Guerrero I; Lopez-Lopez E; Echebarria-Barona A; Zabalza I; Ruiz I; Guerra-Merino I; Garcia-Orad A
    Pharmacogenet Genomics; 2016 Feb; 26(2):100-2. PubMed ID: 26618658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of CEP72 rs924607 TT Genotype with Vincristine-induced Peripheral Neuropathy Measured by Motor Nerve Conduction Studies.
    Kavčič M; Zečkanović A; Jazbec J; Debeljak M
    Klin Padiatr; 2020 Nov; 232(6):331-333. PubMed ID: 32877958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic polymorphisms in candidate genes are not associated with increased vincristine-related peripheral neuropathy in Arab children treated for acute childhood leukemia: a single institution study.
    Zgheib NK; Ghanem KM; Tamim H; Aridi C; Shahine R; Tarek N; Saab R; Abboud MR; El-Solh H; Muwakkit SA
    Pharmacogenet Genomics; 2018 Aug; 28(8):189-195. PubMed ID: 30119132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
    Wunderlich A; Kloess M; Reiser M; Rudolph C; Truemper L; Bittner S; Schmalenberg H; Schmits R; Pfreundschuh M; Loeffler M;
    Ann Oncol; 2003 Jun; 14(6):881-93. PubMed ID: 12796026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Venetoclax with dose-adjusted EPOCH-R as initial therapy for patients with aggressive B-cell lymphoma: a single-arm, multicentre, phase 1 study.
    Rutherford SC; Abramson JS; Bartlett NL; Barta SK; Khan N; Joyce R; Maddocks K; Ali-Shaw T; Senese S; Yuan Y; Westin J; Leonard JP
    Lancet Haematol; 2021 Nov; 8(11):e818-e827. PubMed ID: 34634256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
    Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
    Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular adverse events in patients with non-Hodgkin lymphoma treated with first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP with rituximab (R-CHOP): a systematic review and meta-analysis.
    Linschoten M; Kamphuis JAM; van Rhenen A; Bosman LP; Cramer MJ; Doevendans PA; Teske AJ; Asselbergs FW
    Lancet Haematol; 2020 Apr; 7(4):e295-e308. PubMed ID: 32135128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CNS disease in younger patients with aggressive B-cell lymphoma: an analysis of patients treated on the Mabthera International Trial and trials of the German High-Grade Non-Hodgkin Lymphoma Study Group.
    Schmitz N; Zeynalova S; Glass B; Kaiser U; Cavallin-Stahl E; Wolf M; Haenel M; Loeffler M; Truemper L; Pfreundschuh M
    Ann Oncol; 2012 May; 23(5):1267-1273. PubMed ID: 21989328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of aggressive B-cell lymphoma in elderly patients: influence of single nucleotide polymorphisms affecting pharmacodynamics of chemotherapeutics.
    Melchardt T; Weiss L; Hufnagl C; Neureiter D; Kemmerling R; Morre P; Boekstegers A; Hopfinger G; Auberger J; Steinkirchner S; Pleyer L; Greil R; Egle A
    Leuk Lymphoma; 2015 Feb; 56(2):353-60. PubMed ID: 24798743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined therapy with rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) for Sjögren's syndrome-associated B-cell aggressive non-Hodgkin's lymphomas.
    Voulgarelis M; Giannouli S; Anagnostou D; Tzioufas AG
    Rheumatology (Oxford); 2004 Aug; 43(8):1050-3. PubMed ID: 15187246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of optimal treatment on elderly patients with aggressive non-Hodgkin's lymphoma: more patients treated with unaffected response rates.
    Peters FP; Fickers MM; Erdkamp FL; Wals J; Wils JA; Schouten HC
    Ann Hematol; 2001 Jul; 80(7):406-10. PubMed ID: 11529466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TP53 Arg72 as a favorable prognostic factor for Chinese diffuse large B-cell lymphoma patients treated with CHOP.
    Liu Y; Wang X; Ding N; Mi L; Ping L; Jin X; Li J; Xie Y; Ying Z; Liu W; Zhang C; Deng L; Song Y; Zhu J
    BMC Cancer; 2017 Nov; 17(1):743. PubMed ID: 29126407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomas.
    Sinha R; Kaufman JL; Khoury HJ; King N; Shenoy PJ; Lewis C; Bumpers K; Hutchison-Rzepka A; Tighiouart M; Heffner LT; Lechowicz MJ; Lonial S; Flowers CR
    Cancer; 2012 Jul; 118(14):3538-48. PubMed ID: 22535574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.